Status: Recruiting
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced hepatocellular carcinoma. We aimed to describe the efficacy and safety of locoregional therapy combined with Bevacizumab and PD1/L1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy.
Participants needed: 240
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Sun Yat-sen UniversityUpdated: Aug 14, 2025Locations: 1
Eligibility criteria
HCC diagnosed by histopathological examination or Guidelines for Diagnosis and T... [+8]
Cholangiocellular carcinoma (ICC). [+10]